Literature DB >> 33535553

Identification of RCC Subtype-Specific microRNAs-Meta-Analysis of High-Throughput RCC Tumor microRNA Expression Data.

Arkadiusz Kajdasz1, Weronika Majer2, Katarzyna Kluzek1, Jacek Sobkowiak3, Tomasz Milecki3, Natalia Derebecka2, Zbigniew Kwias3, Hans A R Bluyssen1, Joanna Wesoly2.   

Abstract

Renal cell carcinoma (RCC) is one of the most common cancers worldwide with a nearly non-symptomatic course until the advanced stages of the disease. RCC can be distinguished into three subtypes: papillary (pRCC), chromophobe (chRCC) and clear cell renal cell carcinoma (ccRCC) representing up to 75% of all RCC cases. Detection and RCC monitoring tools are limited to standard imaging techniques, in combination with non-RCC specific morphological and biochemical read-outs. RCC subtype identification relays mainly on results of pathological examination of tumor slides. Molecular, clinically applicable and ideally non-invasive tools aiding RCC management are still non-existent, although molecular characterization of RCC is relatively advanced. Hence, many research efforts concentrate on the identification of molecular markers that will assist with RCC sub-classification and monitoring. Due to stability and tissue-specificity miRNAs are promising candidates for such biomarkers. Here, we performed a meta-analysis study, utilized seven NGS and seven microarray RCC studies in order to identify subtype-specific expression of miRNAs. We concentrated on potentially oncocytoma-specific miRNAs (miRNA-424-5p, miRNA-146b-5p, miRNA-183-5p, miRNA-218-5p), pRCC-specific (miRNA-127-3p, miRNA-139-5p) and ccRCC-specific miRNAs (miRNA-200c-3p, miRNA-362-5p, miRNA-363-3p and miRNA-204-5p, 21-5p, miRNA-224-5p, miRNA-155-5p, miRNA-210-3p) and validated their expression in an independent sample set. Additionally, we found ccRCC-specific miRNAs to be differentially expressed in ccRCC tumor according to Fuhrman grades and identified alterations in their isoform composition in tumor tissue. Our results revealed that changes in the expression of selected miRNA might be potentially utilized as a tool aiding ccRCC subclass discrimination and we propose a miRNA panel aiding RCC subtype distinction.

Entities:  

Keywords:  RCC; ccRCC; meta-analysis; microRNA; renal cancer

Year:  2021        PMID: 33535553     DOI: 10.3390/cancers13030548

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  5 in total

1.  Heterogeneity of Platelet Derived Growth Factor Pathway Gene Expression Profile Defines Three Distinct Subgroups of Renal Cell Carcinomas.

Authors:  Adela Maria Ferician; Ovidiu Catalin Ferician; Andrei Dragos Cumpanas; Patricia Lorena Berzava; Alexandru Nesiu; Ariana Barmayoun; Anca Maria Cimpean
Journal:  Cancer Genomics Proteomics       Date:  2022 Jul-Aug       Impact factor: 3.395

2.  Identification of a Necroptosis-Related Prognostic Index and Associated Regulatory Axis in Kidney Renal Clear Cell Carcinoma.

Authors:  Yong Luo; Guian Zhang
Journal:  Int J Gen Med       Date:  2022-06-03

3.  The Role of microRNAs in Cancer: Functions, Biomarkers and Therapeutics.

Authors:  Paola Tucci
Journal:  Cancers (Basel)       Date:  2022-02-10       Impact factor: 6.639

Review 4.  Integration of Tumor Microenvironment in Patient-Derived Organoid Models Help Define Precision Medicine of Renal Cell Carcinoma.

Authors:  Bingran Wang; Yizheng Xue; Wei Zhai
Journal:  Front Immunol       Date:  2022-05-03       Impact factor: 8.786

5.  Circular RNA Eps15-homology domain-containing protein 2 induce resistance of renal cell carcinoma to sunitinib via microRNA-4731-5p/ABCF2 axis.

Authors:  Wen Li; GaiXia Li; LuQuan Cao
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.